Chronic non-infectious uveitis in the elderly: Epidemiology, pathophysiology and management

Drugs and Aging

Volumn 23, Issue 7, 2006, Pages 535-558

  Gupta, Rajen ^a   Murray, Philip I ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALENDRONIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; ANTIGLAUCOMA AGENT; ANTIMETABOLITE; ATROPINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; CYCLOPENTOLATE; CYCLOPLEGIC AGENT; CYCLOSPORIN; DEXAMETHASONE; ETIDRONIC ACID; FLUOCINOLONE ACETONIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PREDNISOLONE; PREDNISOLONE ACETATE; PROSTAGLANDIN DERIVATIVE; RIMEXOLONE; TRIAMCINOLONE ACETONIDE; TROPICAMIDE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ASEPTIC NECROSIS; BIOLOGICAL THERAPY; BONE METASTASIS; CAROTID ENDARTERECTOMY; CATARACT; CENTRAL NERVOUS SYSTEM; CHORIORETINOPATHY; CHRONIC INFLAMMATION; DEMOGRAPHY; DIAGNOSTIC IMAGING; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; ELDERLY CARE; ELECTRODIAGNOSIS; EYE ALLERGY; EYE SYNECHIA; GLAUCOMA; HUMAN; HYPERCALCEMIA; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSOMNIA; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; ISCHEMIA; KERATOPATHY; LABORATORY TEST; LASER COAGULATION; LENS IMPLANTATION; LETHARGY; LIFE EXPECTANCY; LYMPHOMA; MOOD CHANGE; MUSCLE HYPOTONIA; MYOPATHY; NONHODGKIN LYMPHOMA; OCULAR ISCHEMIC SYNDROME; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTICAL COHERENCE TOMOGRAPHY; OSTEOPOROSIS; PARESTHESIA; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN BRUISING; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; T LYMPHOCYTE; TRABECULECTOMY; UVEA; UVEITIS; VISION; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS OPACITY; WOUND HEALING IMPAIRMENT;

AGED; HUMANS; INCIDENCE; UVEITIS; VISION DISORDERS;

EID: 33748179819     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623070-00001     Document Type: Review

References (147)

1. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987 Feb 15; 103 (2): 234-5
2. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004 Jul-Aug; 218 (4): 223-36
3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005 Sep; 140 (3): 509-16
4. Proposed clinical classification of uveitis. International Uveitis Study Group, 2006. (Data on file)
5. Chang JH, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm 2002 Dec; 10 (4): 263-79
6. Rothova A, van Veenedaal WG, Linssen A, et al. Clinical features of acute anterior uveitis. Am J Ophthalmol 1987 Feb 15; 103 (2): 137-45
7. Suhler EB, Martin TM, Rosenbaum JT. HLA-B27-associated uveitis: overview and current perspectives. Curr Opin Ophthalmol 2003 Dec; 14 (6): 378-83
8. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002 Jul; 14 (4): 337-41
9. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005 Spring; 45 (2): 1-13
10. Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis: incidence and prevalence in a small urban community. Arch Ophthalmol 1962 Oct; 68: 502-14
11. Henderly DE, Genstler AJ, Smith RE, et al. Changing patterns of uveitis. Am J Ophthalmol 1987 Feb 15; 103 (2): 131-6
12. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991 Aug 15; 112 (2): 151-8
13. Perkins ES, Folk J. Uveitis in London and Iowa. Ophthalmologica 1984; 189 (1-2): 36-40
14. Menezo V, Lightman S. The development of complications in patients with chronic anterior uveitis. Am J Ophthalmol 2005 Jun; 139 (6): 988-92
15. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ 2000 Feb 26; 320 (7234): 555-8
16. Whallett AJ, Thurairajan G, Hamburger J, et al. Behçet's syndrome: a multidisciplinary approach to clinical care. QJM 1999 Dec; 92 (12): 727-40
17. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol 2000 Jan; 84 (1): 110-6
18. Jones NP. Fuchs' heterochromic uveitis: an update. Surv Ophthalmol 1993 Jan-Feb; 37 (4): 253-72
19. Bonfioli AA, Curi AL, Orefice F. Fuchs' heterochromic cyclitis. Semin Ophthalmol 2005 Jul-Sep; 20 (3): 143-6
20. Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol 1997 Mar-Apr; 41 (5): 361-94
21. Thach AB, Marak Jr GE, McLean IW, et al. Phacoanaphylactic endophthalmitis: a clinicopathologic review. Int Ophthalmol 1991 Jul; 15 (4): 271-9
22. Stavrou P, Mitchell SM, Fox JD, et al. Detection of varicella-zoster virus DNA in ocular samples from patients with uveitis but no cutaneous eruption. Eye 1994; 8 Pt 6: 684-7
23. Bonfioli AA, Damico FM, Curi AL, et al. Intermediate uveitis. Semin Ophthalmol 2005 Jul-Sep; 20 (3): 147-54
24. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 2001 Nov-Dec; 46 (3): 209-33
25. Jones NP. Sarcoidosis and uveitis. Ophthalmol Clin North Am 2002 Sep; 15 (3): 319-26, vi
26. Pavesio CE, Lightman S. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Br J Ophthalmol 1996 Dec; 80 (12): 1099-107
27. Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol 2005 Nov-Dec; 50 (6): 519-41
28. Office for National Statistics. Population estimates: UK population approaches 60 million [online]. Available from URL: http://www.statistics.gov. uk/CCI/nugget.asp?.ID=6 [Accessed 2006 Feb 15]
29. Dandona L, Dandona R, John RK, et al. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol 2000 Jul; 84 (7): 706-9
30. Guex-Crosier Y. Epidemiology of uveitis [in French]. Rev Prat 1999 Nov 15; 49 (18): 1989-94
31. Barton K, Pavesio CE, Towler HM, et al. Uveitis presenting de novo in the elderly. Eye 1994; 8 (Pt 3): 288-91
32. Favre C, Tran VT, Herbort CP. Uveitis in the elderly [in French]. Klin Monatsbl Augenheilkd 1994 May; 204 (5): 319-22
33. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004 Mar; 111 (3): 491-500
34. Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology 2006 Feb; 113 (2): 307, e1
35. Tran VT, Auer C, Guex-Crosier Y, et al. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994; 18 (5): 293-8
36. Makley Jr TA, Orlando RG. Uveitis in older patients. Ann Ophthalmol 1982 Oct; 14 (10): 942-4
37. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996 May; 114 (5): 593-9
38. Gilbert RE, Dunn DT, Lightman S, et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol Infect 1999 Oct; 123 (2): 283-9
39. Sullivan C, Murray PI. Acquired ocular toxoplasmosis in an elderly patient. Eye 2001 Dec; 15 (Pt 6): 791-2
40. Chatzistefanou K, Markomichelakis NN, Christen W, et al. Characteristics of uveitis presenting for the first time in the elderly. Ophthalmology 1998 Feb; 105 (2): 347-52
41. Becker MD, Smith JR, Max R, et al. Management of sight-threatening uveitis: new therapeutic options. Drugs 2005; 65 (4): 497-519
42. Forrester JV. Uveitis: pathogenesis. Lancet 1991 Dec 14; 338 (8781): 1498-501
43. Lightman S. Uveitis: what do we know and how does it help? Clin Experiment Ophthalmol 2001 Apr; 29 (2): 48-51
44. Whitcup SM, Nussenblatt RB. Immunologic mechanisms of uveitis: new targets for immunomodulation. Arch Ophthalmol 1997 Apr; 115 (4): 520-5
45. Dick AD. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin 2000 Spring; 40 (2): 1-18
46. Durrani OM, Curnow SJ, Faint JM, et al. Enumeration, characterisation and clinical correlation of cellular infiltrate in uveitis [abstract no. 3067]. Invest Ophthmol Vis Sci 2001; 42 (4): S571
47. Curnow SJ, Faint JM, Durrani OM, et al. CD4+ and CD8+ lymphocytes of naive and memory phenotype in uveitis [abstract no. 4940]. Invest Ophthalmol Vis Sci 2001; 42 (2): S919
48. Murray PI, Clay CD, Mappin C, et al. Molecular analysis of resolving immune responses in uveitis. Clin Exp Immunol 1999 Sep; 117 (3): 455-61
49. Murray PI, Young DW. Soluble interleukin-2 receptors in retinal vasculitis. Curr Eye Res 1992; 11 Suppl.: 193-5
50. Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998 May; 39 (6): 996-1004
51. Dick AD, Cheng YF, Purdie AT, et al. Immunocytochemical analysis of blood lymphocytes in uveitis. Eye 1992; 6 (Pt 6): 643-7
52. Dick AD, Siepmann K, Dees C, et al. Fas-Fas ligand-mediated apoptosis within aqueous during idiopathic acute anterior uveitis. Invest Ophthalmol Vis Sci 1999 Sep; 40 (10): 2258-67
53. Curnow SJ, Rauz S, Durrani OM, et al. Inhibition of spontaneous lymphocyte apoptosis contributes to the breakdown of immune privilege in uveitis [abstract]. In: Annual meeting abstract search and program planner (on CD-ROM). Association for Research in Vision and Ophthalmology 2002, 1535
54. Streilein JW, Taylor AW. Local immunosuppression: the eye. In: Thompson A, editor. Therapeutic immunosuppression (immunology and medicine series). Dordrecht: Kluwer Academic, 2001: 275-322
55. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003 Nov; 3 (11): 879-89
56. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995 Nov 17; 270 (5239): 1189-92
57. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003 Aug; 74 (2): 179-85
58. Curnow SJ, Scheel-Toellner D, Jenkinson W, et al. Inhibition T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 2004 Oct 15; 173 (8): 5290-7
59. Murray PI, Hoekzema R, van Haren MA, et al. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci 1990 May; 31 (5): 917-20
60. Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005 Nov; 46 (11): 4251-9
61. Kirsch O, Lautier-Frau M, Labetoulle M, et al. Characteristics of uveitis presenting de novo in the elderly [in French]. J Ophtalmol 2003 Sep; 26 (7): 720-4
62. Ikeda N, Hayasaka S, Hayasaka Y. Uveitis and pseudouveitis presenting for the first time in Japanese elderly patients. Ophthalmologica 2005 Sep-Oct; 219 (5): 263-6
63. Jacobs NA, Ridgway AE. Syndrome of ischaemic ocular inflammation: six cases and a review. Br J Ophthalmol 1985 Sep; 69 (9): 681-7
64. Malhotra R, Gregory-Evans K. Management of ocular ischaemic syndrome. Br J Ophthalmol 2000 Dec; 84 (12): 1428-31
65. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet 1999 Jun 19; 353 (9170): 2105-10
66. Rothova A, Meenken C, Michels RP, et al. Uveitis and diabetes mellitus. Am J Ophthalmol 1988 Jul 15; 106 (1): 17-20
67. Murray PI, Russell-Eggitt IM. An unusual presentation of diabetes mellitus. Metab Pediatr Syst Ophthalmol 1991; 14 (1): 16-7
68. Joslin EP. Joslin's diabetes mellitus. 12th ed. Philadelphia (PA): Lea & Febiger, 1985
69. Read RW, Zamir E, Rao NA. Neoplastic masquerade syndromes. Surv Ophthalmol 2002 Mar-Apr; 47 (2): 81-124
70. Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 2005 Aug; 19 (4): 739-49, viii
71. Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 1987 Dec; 94 (12): 1631-9
72. Stanbury RM, Graham EM, Murray PI. Sarcoidosis. Int Ophthalmol Clin 1995 Summer; 35 (3): 123-37
73. Lardenoye CW, Van der Lelij A, de Loos WS, et al. Peripheral multifocal chorioretinitis: a distinct clinical entity? Ophthalmology 1997 Nov; 104 (11): 1820-6
74. McCluskey P, Powell RJ. The eye in systemic inflammatory diseases. Lancet 2004 Dec 11-17; 364 (9451): 2125-33
75. Edelsten C, Pearson A, Joynes E, et al. The ocular and systemic prognosis of patients presenting with sarcoid uveitis. Eye 1999 Dec; 13 (Pt 6): 748-53
76. Stavrou P, Linton S, Young DW, et al. Clinical diagnosis of ocular sarcoidosis. Eye 1997; 11 (Pt 3): 365-70
77. Kaiser PK, Lowder CY, Sullivan P, et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol 2002 Apr; 133 (4): 499-505
78. Sobrin L, Lam BL, Liu M, et al. Electroretinographic monitoring in birdshot chorioretinopathy. Am J Ophthalmol 2005 Jul; 140 (1): 52-64
79. Holder GE, Robson AG, Pavesio C, et al. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol 2005 Jun; 89 (6): 709-18
80. Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998 May-Jun; 42 (6): 557-70
81. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999 Oct; 15 (4): 285-96
82. Siris ES. Bisphosphonates and iritis. Lancet 1993 Feb 13; 341 (8842): 436-7
83. De S, Meyer P, Crisp AJ. Pamidronate and uveitis [letter]. Br J Rheumatol 1995 May; 34 (5): 479
84. Haverbeke G, Pertile G, Claes C, et al. Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtalmol 2003; (290): 71-6
85. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999 Jun; 117 (6): 837-8
86. ten Doesschate J. Causes of blindness in The Netherlands. Doc Ophthalmol 1982 Jan 29; 52 (3-4): 279-85
87. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990 Oct; 14 (5-6): 303-8
88. Krumpaszky HG, Klauss V. Cause of blindness in Bavaria: evaluation of a representative sample from blindness compensation records of Upper Bavaria [in German]. Klin Monatsbl Augenheilkd 1992 Feb; 200 (2): 142-6
89. Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004 Sep; 88 (9): 1159-62
90. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma 2004 Dec; 13 (6): 461-5
91. Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 2001 Jul; 80 (4): 263-70
92. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995 Jun 24; 345 (8965): 1604-6
93. Hooper PL, Rao NA, Smith RE. Cataract extraction in uveitis patients. Surv Ophthalmol 1990 Sep-Oct; 35 (2): 120-44
94. Muccioli C, Belfort Jr R. Cataract surgery in patients with uveitis. Int Ophthalmol Clin 2000 Spring; 40 (2): 163-73
95. Foster CS, Rashid S. Management of coincident cataract and uveitis. Curr Opin Ophthalmol 2003 Feb; 14 (1): 1-6
96. Rauz S, Stavrou P, Murray PI. Evaluation of foldable intraocular lenses in patients with uveitis. Ophthalmology 2000 May; 107 (5): 909-19
97. The Royal College of Ophthalmologists. Cataract surgery guidelines 2004 [online]. Available from URL: http://www.rcophth.ac.uk/about/publications/ [Accessed 2006 March 18]
98. Murray P. Serum autoantibodies and uveitis. Br J Ophthalmol 1986 Apr; 70 (4): 266-8
99. Rahi AH, Tabbara KF. Laboratory investigations in posterior uveitis. Int Ophthalmol Clin 1995 Summer; 35 (3): 59-74
100. Wade NK. Diagnostic testing in patients with ocular inflammation. Int Ophthalmol Clin 2000 Spring; 40 (2): 37-54
101. Heiden D, Nozik RA. A systemic approach to uveitis diagnosis. Ophthalmol Clin North Am 1993; 6: 13-22
102. Rosenbaum JT, Wernick R. Selection and interpretation of laboratory tests for patients with uveitis. Int Ophthalmol Clin 1990 Fall; 30 (4): 238-43
103. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997 Dec; 81 (12): 1107-12
104. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992 Mar; 76 (3): 137-41
105. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996 Apr; 80 (4): 332-6
106. Nussenblatt RB, Whitcup SM. Uveitis: fundamentals and clinical practice. 3rd ed. Philadelphia (PA): Mosby, 2004
107. Weinreb RN, Tessler H. Laboratory diagnosis of ophthalmic sarcoidosis. Surv Ophthalmol 1984 May-Jun; 28 (6): 653-64
108. International Study Group for Behçet's Disease. Criteria for diagnosis of Beḩcet's disease. Lancet 1990 May 5; 335 (8697): 1078-80
109. Levinson RD, Brezin A, Rothova A, et al. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 2006 Jan; 141 (1): 185-7
110. Ciardella AP, Prall FR, Borodoker N, et al. Imaging techniques for posterior uveitis. Curr Opin Ophthalmol 2004 Dec; 15 (6): 519-30
111. De Laey JJ. Fluorescein angiography in posterior uveitis. Int Ophthalmol Clin 1995 Summer; 35 (3): 33-58
112. Tran VT, LeHoang P, Herbort CP. Value of high-frequency ultrasound biomicroscopy in uveitis. Eye 2001 Feb; 15 (Pt 1): 23-30
113. Antcliff RJ, Stanford MR, Chauhan DS, et al. Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoid macular edema in patients with uveitis. Ophthalmology 2000 Mar; 107 (3): 593-9
114. Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol 2004 Apr; 88 (4): 582-3
115. Lightman S. Uveitis: management. Lancet 1991 Dec 14; 338 (8781): 1501-4
116. Murray PI. Idiopathic (autoimmune) sight threatening uveitis. In: Wormald R, Smeeth L, Henshaw K, editors. Evidence-based ophthalmology. London: BMJ Books, 2004: 167-73
117. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000 Oct; 130 (4): 492-513
118. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994; 8 (Pt 1): 66-9
119. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, et al. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999 Apr; 237 (4): 289-95
120. Okada AA, Wakabayashi T, Morimura Y, et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 2003 Aug; 87 (8): 968-71
121. Levin DS, Han DP, Dev S, et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol 2002 Feb; 133 (2): 196-202
122. Tehrani NN, Saeed T, Murray PI. Deep intramuscular methyl-prednisolone for the treatment of cystoid macular oedema in uveitis. Eye 2000 Oct; 14 Pt 5: 691-4
123. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis [letter]. Br J Ophthalmol 2003 Mar; 87 (3): 361
124. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001 Feb; 29 (1): 2-6
125. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005 Nov; 112 (11): 1916-21
126. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 Jun; 113 (6): 1020-7
127. The Bone and Tooth Society NOS, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP, 2002
128. Jones NP, Anderton LC, Cheong FM, et al. Corticosteroid-induced osteoporosis in patients with uveitis. Eye 2002 Sep; 16 (5): 587-93
129. Myllykangas-Luosujarvi R, Aho K, Isomaki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995 Dec; 22 (12): 2214-7
130. Menezo V, Lau C, Comer M, et al. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Experiment Ophthalmol 2005 Feb; 33 (1): 16-21
131. Smith JR. Management of uveitis. Clin Exp Med 2004 Sep; 4 (1): 21-9
132. Pascalis L, Pia G, Aresu G, et al. Combined cyclosporin Asteroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993 Aug; 6 (4): 467-80
133. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001 Jun; 108 (6): 1134-9
134. Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003 Jun; 11 (2): 131-9
135. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990 Feb 1; 322 (5): 281-5
136. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004 Dec; 151 (6): 1123-32
137. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998 Jul 4; 352 (9121): 35-6
138. Siepmann K, Huber M, Stubiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244 (7): 788-94
139. Zierhut M, Stubiger N, Aboalchamat W, et al. Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis[in German]. Ophthalmologe 2001 Jul; 98 (7): 647-51
140. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003 Dec; 31 (6): 487-91
141. Hesselink DA, Baarsma GS, Kuijpers RW, et al. Experience with cyclosporine in endogenous uveitis posterior. Transplant Proc 2004 Mar; 36 (2 Suppl.): 372S-7S
142. Lustig MJ, Cunningham Jr ET. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol 2003 Dec; 14 (6): 399-412
143. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005 Jun; 89 (6): 666-9
144. Murray PI, Sivaraj RR. Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Eye 2005 Aug; 19 (8): 831-3
145. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990 Aug; 4 (11): 2860-7
146. Mushtaq BST, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 2006 Apr 7. Epub ahead of print
147. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005 Dec; 140 (6): 1096-105